Prostate Cancer - Results from #22860

Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: Can PSA and PSA density help in patient selection? - Abstract June 25, 2013

High-risk prostate cancer: Combination of high-dose, high-precision radiotherapy and androgen deprivation therapy - Abstract June 24, 2013

Plasma-seq: A novel strategy for metastatic prostate cancer analysis - Abstract June 24, 2013

Treatment of local-regional prostate cancer detected by PSA screening: Benefits and harms according to prognostic factors - Abstract June 24, 2013

Coffee consumption and the risk of prostate cancer: The Ohsaki Cohort Study - Abstract June 24, 2013

MR imaging of prostate cancer in radiation oncology: What radiologists need to know - Abstract June 24, 2013

Methotrexate therapy leading to a rapid progression of a previously indolent prostate cancer: Is immunosuppression to blame? - Abstract June 24, 2013

A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy - Abstract June 24, 2013

Outcome of radical prostatectomy in patients meeting criteria for active surveillance - Abstract June 24, 2013

Does periprostatic block increase the transrectal ultrasound (TRUS) biopsy sepsis rate in men with elevated PSA? - Abstract June 24, 2013

Perspectives on treatment of metastatic castration-resistant prostate cancer - Abstract June 21, 2013

Reducing rectal injury during external beam radiotherapy for prostate cancer - Abstract June 21, 2013

Agent Orange as a risk factor for high-grade prostate cancer - Abstract June 21, 2013

Role of (18)F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer - Abstract June 21, 2013

Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer - Abstract June 21, 2013

Canadian prostate brachytherapy in 2012 - Abstract June 21, 2013

Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists - Abstract June 21, 2013

Incremental costs of prostate cancer trials: Are clinical trials really a burden on a public payer system? - Abstract June 21, 2013

Metastatic prostate cancer with malignant ascites: A case report and literature review - Abstract June 21, 2013

A current perspective on the use of genomics in the diagnosis and treatment of prostate cancer, an interview with Stephen J. Freedland, MD June 21, 2013

Page 1144 of 1435